Enigma Management Corp Dba Alliance Laboratory

Enigma Management Corp Dba Alliance Laboratory was paid $3.85M by Medicaid between Jan 2018 and Dec 2024, across 159 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 32% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#34 of 116

Median peer was paid$618K

This provider vs. median6.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	7,809	$189K
2019	14,459	$480K
2020	21,598	$925K
2021	44,401	$1.11M
2022	66,193	$815K
2023	28,526	$172K
2024incomplete	28,143	$163K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	32%	12,898	11,034	$1.25M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	29%	22,720	15,632	$1.13M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	6.1%	17,554	12,113	$234K
87631		4.3%	4,471	3,424	$166K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3.2%	17,663	12,188	$124K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.9%	4,360	4,186	$75K
80050	General health panel	1.7%	3,040	2,880	$66K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.5%	2,736	2,250	$59K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.4%	5,337	3,390	$53K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.3%	340	319	$50K
87486		1.0%	2,593	2,113	$39K
87581		<1%	2,595	2,115	$38K

147 more codes

82607		<1%	4,553	$31K
86769		<1%	1,307	$30K
83036	Hemoglobin; glycosylated (A1C)	<1%	5,980	$29K
82746		<1%	3,745	$27K
82728		<1%	3,143	$24K
82784		<1%	1,426	$21K
86317		<1%	1,659	$19K
80061	Lipid panel	<1%	6,119	$19K
84439		<1%	4,243	$19K
84481		<1%	4,098	$18K
84153		<1%	1,556	$18K
84403		<1%	1,539	$16K
86141		<1%	2,711	$15K
86803		<1%	2,183	$14K
83970		<1%	734	$13K
86328		<1%	452	$13K
86703		<1%	1,058	$10K
86704		<1%	1,523	$10K
87340		<1%	1,446	$10K
86708		<1%	1,490	$10K
80053	Comprehensive metabolic panel	<1%	3,669	$10K
81000		<1%	5,127	$8K
82785		<1%	1,286	$8K
84165		<1%	1,812	$8K
84550		<1%	2,797	$7K
83090		<1%	852	$7K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	1,828	$6K
86160		<1%	548	$6K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	4,529	$6K
84443	Thyroid stimulating hormone (TSH)	<1%	2,152	$5K
81408		<1%	266	$5K
81162		<1%	269	$5K
83001		<1%	436	$4K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	87	$4K
83540		<1%	1,870	$4K
86481		<1%	243	$4K
86003		<1%	236	$4K
87481		<1%	143	$4K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	4,003	$4K
83550		<1%	1,506	$4K
84270		<1%	915	$3K
86235		<1%	550	$3K
84480		<1%	2,561	$3K
84100		<1%	1,171	$3K
86038		<1%	902	$3K
86735		<1%	607	$2K
84402		<1%	411	$2K
83002		<1%	294	$2K
82977		<1%	1,192	$2K
86480		<1%	196	$2K
86431		<1%	882	$2K
83615		<1%	825	$2K
81226		<1%	305	$2K
81201		<1%	247	$2K
85651		<1%	1,847	$2K
86200		<1%	502	$2K
81405		<1%	248	$2K
82670		<1%	171	$2K
86592		<1%	858	$2K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	84	$2K
81406		<1%	245	$2K
81328		<1%	341	$2K
86706		<1%	788	$2K
82043		<1%	544	$2K
81321		<1%	265	$1K
81298		<1%	249	$1K
81404		<1%	243	$1K
86762		<1%	419	$1K
83735		<1%	908	$1K
81225		<1%	304	$1K
81401		<1%	644	$1K
81212		<1%	266	$1K
81317		<1%	247	$1K
86765		<1%	408	$1K
82570		<1%	571	$1K
86695		<1%	267	$1K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	602	$992.79
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	114	$928.26
81293		<1%	209	$908.93
81227		<1%	311	$867.64
81231		<1%	333	$867.06
81230		<1%	310	$867.06
81295		<1%	249	$840.29
81241		<1%	342	$822.30
82550		<1%	396	$810.52
87500		<1%	77	$747.08
83986		<1%	360	$696.18
82533		<1%	94	$682.97
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	98	$682.82
86376		<1%	159	$678.11
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	112	$669.21
87653		<1%	122	$643.28
81291		<1%	339	$635.08
85730		<1%	180	$597.80
86787		<1%	343	$582.27
87086	Culture, bacterial; quantitative colony count, urine	<1%	193	$537.47
87640		<1%	96	$530.74
83525		<1%	125	$496.63
85044		<1%	724	$494.89
82378		<1%	77	$492.32
84144		<1%	94	$482.02
86800		<1%	97	$432.20
86304		<1%	35	$421.47
85610		<1%	193	$406.90
81240		<1%	341	$402.84
82627		<1%	25	$344.41
84305		<1%	61	$343.83
84152		<1%	15	$340.65
83690		<1%	193	$339.86
81403		<1%	242	$333.36
86780		<1%	65	$327.18
86300		<1%	24	$325.87
86301		<1%	34	$313.03
84425		<1%	26	$279.86
84446		<1%	32	$268.96
87641		<1%	50	$259.62
83785		<1%	13	$255.11
82108		<1%	13	$243.91
84702		<1%	63	$220.65
84590		<1%	32	$220.21
84466		<1%	75	$219.64
82150		<1%	114	$212.30
84146		<1%	41	$212.09
83018		<1%	13	$195.80
82175		<1%	15	$189.54
82300		<1%	15	$184.02
83020		<1%	27	$175.25
82180		<1%	29	$163.55
83825		<1%	15	$162.46
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	85	$149.36
84630		<1%	29	$139.63
84445		<1%	12	$127.15
82525		<1%	15	$124.01
83655		<1%	15	$121.04
84133		<1%	46	$115.49
86618		<1%	15	$102.18
84255		<1%	15	$75.89
84154		<1%	55	$63.20
84436		<1%	12	$57.00
82248		<1%	123	$52.65
84300		<1%	18	$45.30
80048	Basic metabolic panel (calcium, ionized)	<1%	152	$21.89
82040		<1%	59	$9.90
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	0%	25	$0.00
84155		0%	29	$0.00
81292		0%	38	$0.00
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	0%	21	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialABRAZI, BELLA (COO)

Same official

Other billing entities under ABRAZI, BELLA

Full network →

Provider	Location	Paid
Up Services INC	Boca Raton, FL	$3.94M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.